News and Press Releases
Press releases
Theralase® Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five and Six
Patient Five and Six Demonstrate No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Company Successfully Completes 180 days Follow Up of ...
0Theralase® Releases 2Q2018 Financial Statements
Toronto, Ontario – July 26, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stag...
0Theralase® Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment
Patient Five Demonstrates No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Toronto, Ontario – July 16, 2018 Theralase Technologies In...
0Theralase® Releases AGM Videos
Toronto, Ontario – June 29, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stag...
0Theralase® Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin® Based Photo Dynamic Therapy, in Immune Privileged Sites
Toronto, Ontario – June 22, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stag...
0Theralase® Demonstrates Significant Advantage in Treatment of Brain Tumours
Toronto, Ontario – June 11, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinica...
0Theralase® Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase Medical and Scientific Advisory Board concluded that the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Stu...
0Theralase® Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Patient Five Shows No Clinical Evidence or Presence of NMIBC at 90 Day Cystoscopy Analysis Patient Six Shows No Clinical Evidence or Presence of NM...
0Theralase® Increases Revenue 22% for 2017 Financial Statements
Toronto, Ontario – April 30, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical sta...
0Theralase® Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Patient Six Demonstrates No Clinical Evidence of NMIBC at 90 Day Cystoscopy Analysis Toronto, Ontario – May 17, 2018 Theralase Technologies Inc. ...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.